Cargando…
Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study
OBJECTIVE: To assess the medication and disease burden of young adults with juvenile idiopathic arthritis (JIA). METHODS: Young adults with JIA prospectively followed in the Juvenile Arthritis Methotrexate/Biologics long-term Observation reported on their health status and medication use. All medica...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608545/ https://www.ncbi.nlm.nih.gov/pubmed/36283758 http://dx.doi.org/10.1136/rmdopen-2022-002520 |
_version_ | 1784818799339372544 |
---|---|
author | Montag, Laura J Horneff, Gerd Hoff, Paula Klein, Ariane Kallinich, Tilmann Foeldvari, Ivan Seipelt, Eva Tatsis, Stefanie Peer Aries, MD Niewerth, Martina Klotsche, Jens Minden, Kirsten |
author_facet | Montag, Laura J Horneff, Gerd Hoff, Paula Klein, Ariane Kallinich, Tilmann Foeldvari, Ivan Seipelt, Eva Tatsis, Stefanie Peer Aries, MD Niewerth, Martina Klotsche, Jens Minden, Kirsten |
author_sort | Montag, Laura J |
collection | PubMed |
description | OBJECTIVE: To assess the medication and disease burden of young adults with juvenile idiopathic arthritis (JIA). METHODS: Young adults with JIA prospectively followed in the Juvenile Arthritis Methotrexate/Biologics long-term Observation reported on their health status and medication use. All medications taken (disease-modifying antirheumatic drugs (DMARDs)/prescription/over-the-counter drugs, but excluding most local therapies) classified according to the Anatomical Therapeutic Chemical Classification System were included in this analysis. Medication use at last follow-up was evaluated by sex, JIA category and time from symptom onset to the first biological DMARD (bDMARD) start. RESULTS: A total of 1306 young adults (68% female) with JIA and a mean disease duration of 13.6±6 years were included in the study. Patients reported using on average 2.4±2.1 medicines and 1.5±1.7 non-DMARD medicines, respectively, at the last follow-up. Almost a quarter of the patients reported polypharmacy. The higher the number of medications used was, the higher the disease activity, pain and fatigue, and the lower the quality of life of patients. Medication usage differed significantly between sexes and JIA categories, being highest in patients with rheumatoid factor-positive polyarthritis and systemic JIA. The number of medications used was significantly associated with the time from symptom onset to bDMARD start. Patients taking opioids or antidepressants had a particularly high disease burden and had received bDMARDs an average of 2 years later than patients not taking these medications. CONCLUSION: Medication use in adults with JIA varies depending on sex, JIA category, and the time between symptom onset and initiation of treatment with bDMARD. |
format | Online Article Text |
id | pubmed-9608545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-96085452022-10-28 Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study Montag, Laura J Horneff, Gerd Hoff, Paula Klein, Ariane Kallinich, Tilmann Foeldvari, Ivan Seipelt, Eva Tatsis, Stefanie Peer Aries, MD Niewerth, Martina Klotsche, Jens Minden, Kirsten RMD Open Paediatric Rheumatology OBJECTIVE: To assess the medication and disease burden of young adults with juvenile idiopathic arthritis (JIA). METHODS: Young adults with JIA prospectively followed in the Juvenile Arthritis Methotrexate/Biologics long-term Observation reported on their health status and medication use. All medications taken (disease-modifying antirheumatic drugs (DMARDs)/prescription/over-the-counter drugs, but excluding most local therapies) classified according to the Anatomical Therapeutic Chemical Classification System were included in this analysis. Medication use at last follow-up was evaluated by sex, JIA category and time from symptom onset to the first biological DMARD (bDMARD) start. RESULTS: A total of 1306 young adults (68% female) with JIA and a mean disease duration of 13.6±6 years were included in the study. Patients reported using on average 2.4±2.1 medicines and 1.5±1.7 non-DMARD medicines, respectively, at the last follow-up. Almost a quarter of the patients reported polypharmacy. The higher the number of medications used was, the higher the disease activity, pain and fatigue, and the lower the quality of life of patients. Medication usage differed significantly between sexes and JIA categories, being highest in patients with rheumatoid factor-positive polyarthritis and systemic JIA. The number of medications used was significantly associated with the time from symptom onset to bDMARD start. Patients taking opioids or antidepressants had a particularly high disease burden and had received bDMARDs an average of 2 years later than patients not taking these medications. CONCLUSION: Medication use in adults with JIA varies depending on sex, JIA category, and the time between symptom onset and initiation of treatment with bDMARD. BMJ Publishing Group 2022-10-25 /pmc/articles/PMC9608545/ /pubmed/36283758 http://dx.doi.org/10.1136/rmdopen-2022-002520 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Paediatric Rheumatology Montag, Laura J Horneff, Gerd Hoff, Paula Klein, Ariane Kallinich, Tilmann Foeldvari, Ivan Seipelt, Eva Tatsis, Stefanie Peer Aries, MD Niewerth, Martina Klotsche, Jens Minden, Kirsten Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study |
title | Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study |
title_full | Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study |
title_fullStr | Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study |
title_full_unstemmed | Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study |
title_short | Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study |
title_sort | medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study |
topic | Paediatric Rheumatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608545/ https://www.ncbi.nlm.nih.gov/pubmed/36283758 http://dx.doi.org/10.1136/rmdopen-2022-002520 |
work_keys_str_mv | AT montaglauraj medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy AT horneffgerd medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy AT hoffpaula medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy AT kleinariane medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy AT kallinichtilmann medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy AT foeldvariivan medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy AT seipelteva medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy AT tatsisstefanie medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy AT peerariesmd medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy AT niewerthmartina medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy AT klotschejens medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy AT mindenkirsten medicationburdeninyoungadultswithjuvenileidiopathicarthritisdatafromamulticentreobservationalstudy |